Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database

Elias Jabbour; Matthias Stelljes; Anjali S. Advani; Daniel J. DeAngelo; Nicola Gökbuget; David I. Marks; Wendy Stock; Susan O’Brien; Ryan D. Cassaday; Tao Wang; Alexander Neuhof; Erik Vandendries; Hagop Kantarjian

doi:10.1080/10428194.2020.1751839

Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database

Elias Jabbour, Matthias Stelljes, Anjali S. Advani, Daniel J. DeAngelo, Nicola Gökbuget, David I. Marks, Wendy Stock, Susan O’Brien, Ryan D. Cassaday, Tao Wang, Alexander Neuhof, Erik Vandendries, Hagop Kantarjian

Leukemia

Research output: Contribution to journal › Letter › peer-review

10 Scopus citations

Original language	English (US)
Pages (from-to)	2012-2015
Number of pages	4
Journal	Leukemia and Lymphoma
Volume	61
Issue number	8
DOIs	https://doi.org/10.1080/10428194.2020.1751839
State	Published - Jul 2 2020

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1080/10428194.2020.1751839

Cite this

Jabbour, E., Stelljes, M., Advani, A. S., DeAngelo, D. J., Gökbuget, N., Marks, D. I., Stock, W., O’Brien, S., Cassaday, R. D., Wang, T., Neuhof, A., Vandendries, E., & Kantarjian, H. (2020). Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database. Leukemia and Lymphoma, 61(8), 2012-2015. https://doi.org/10.1080/10428194.2020.1751839

Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database. / Jabbour, Elias; Stelljes, Matthias; Advani, Anjali S. et al.
In: Leukemia and Lymphoma, Vol. 61, No. 8, 02.07.2020, p. 2012-2015.

Research output: Contribution to journal › Letter › peer-review

Jabbour, E, Stelljes, M, Advani, AS, DeAngelo, DJ, Gökbuget, N, Marks, DI, Stock, W, O’Brien, S, Cassaday, RD, Wang, T, Neuhof, A, Vandendries, E & Kantarjian, H 2020, 'Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database', Leukemia and Lymphoma, vol. 61, no. 8, pp. 2012-2015. https://doi.org/10.1080/10428194.2020.1751839

@article{e02d62f6649047688630fe784208b292,

title = "Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database",

author = "Elias Jabbour and Matthias Stelljes and Advani, {Anjali S.} and DeAngelo, {Daniel J.} and Nicola G{\"o}kbuget and Marks, {David I.} and Wendy Stock and Susan O{\textquoteright}Brien and Cassaday, {Ryan D.} and Tao Wang and Alexander Neuhof and Erik Vandendries and Hagop Kantarjian",

note = "Funding Information: This study was sponsored by Pfizer. Medical writing support was provided by Susan Tan, PhD, of Engage Scientific Solutions, and was funded by Pfizer. The first draft of this manuscript was based on poster PS950 presented at the 24th Congress of the European Hematology Association (EHA), 2019, and poster 7029 presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, 2019. Funding Information: This study was sponsored by Pfizer. Medical writing support was provided by Susan Tan, PhD, of Engage Scientific Solutions, and was funded by Pfizer. The first draft of this manuscript was based on poster PS950 presented at the 24th Congress of the European Hematology Association (EHA), 2019, and poster 7029 presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, 2019. ",

year = "2020",

month = jul,

day = "2",

doi = "10.1080/10428194.2020.1751839",

language = "English (US)",

volume = "61",

pages = "2012--2015",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "8",

}

TY - JOUR

T1 - Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia

T2 - an update from the INO-VATE final study database

AU - Jabbour, Elias

AU - Stelljes, Matthias

AU - Advani, Anjali S.

AU - DeAngelo, Daniel J.

AU - Gökbuget, Nicola

AU - Marks, David I.

AU - Stock, Wendy

AU - O’Brien, Susan

AU - Cassaday, Ryan D.

AU - Wang, Tao

AU - Neuhof, Alexander

AU - Vandendries, Erik

AU - Kantarjian, Hagop

N1 - Funding Information: This study was sponsored by Pfizer. Medical writing support was provided by Susan Tan, PhD, of Engage Scientific Solutions, and was funded by Pfizer. The first draft of this manuscript was based on poster PS950 presented at the 24th Congress of the European Hematology Association (EHA), 2019, and poster 7029 presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, 2019. Funding Information: This study was sponsored by Pfizer. Medical writing support was provided by Susan Tan, PhD, of Engage Scientific Solutions, and was funded by Pfizer. The first draft of this manuscript was based on poster PS950 presented at the 24th Congress of the European Hematology Association (EHA), 2019, and poster 7029 presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, 2019.

PY - 2020/7/2

Y1 - 2020/7/2

UR - http://www.scopus.com/inward/record.url?scp=85084301871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85084301871&partnerID=8YFLogxK

U2 - 10.1080/10428194.2020.1751839

DO - 10.1080/10428194.2020.1751839

M3 - Letter

C2 - 32378440

AN - SCOPUS:85084301871

SN - 1042-8194

VL - 61

SP - 2012

EP - 2015

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 8

ER -

Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this